These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 34699647)

  • 1. Safety and potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical study.
    Abdoli A; Aalizadeh R; Aminianfar H; Kianmehr Z; Teimoori A; Azimi E; Emamipour N; Eghtedardoost M; Siavashi V; Jamshidi H; Hosseinpour M; Taqavian M; Jalili H
    Rev Med Virol; 2022 May; 32(3):e2305. PubMed ID: 34699647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern.
    Salehi M; Hosseini H; Jamshidi HR; Jalili H; Tabarsi P; Mohraz M; Karimi H; Lotfinia M; Aalizadeh R; Mohammadi M; Ramazi S; Abdoli A
    Clin Microbiol Infect; 2022 Jun; 28(6):882.e1-882.e7. PubMed ID: 35248745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.
    Wang H; Zhang Y; Huang B; Deng W; Quan Y; Wang W; Xu W; Zhao Y; Li N; Zhang J; Liang H; Bao L; Xu Y; Ding L; Zhou W; Gao H; Liu J; Niu P; Zhao L; Zhen W; Fu H; Yu S; Zhang Z; Xu G; Li C; Lou Z; Xu M; Qin C; Wu G; Gao GF; Tan W; Yang X
    Cell; 2020 Aug; 182(3):713-721.e9. PubMed ID: 32778225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice.
    Turan RD; Tastan C; Dilek Kancagi D; Yurtsever B; Sir Karakus G; Ozer S; Abanuz S; Cakirsoy D; Tumentemur G; Demir S; Seyis U; Kuzay R; Elek M; Kocaoglu ME; Ertop G; Arbak S; Acikel Elmas M; Hemsinlioglu C; Hatirnaz Ng O; Akyoney S; Sahin I; Kayhan CK; Tokat F; Akpinar G; Kasap M; Kocagoz AS; Ozbek U; Telci D; Sahin F; Yalcin K; Ratip S; Ince U; Ovali E
    Sci Rep; 2021 Aug; 11(1):15799. PubMed ID: 34349145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial.
    Mohraz M; Vahdat K; Ghamari SH; Abbasi-Kangevari M; Ghasemi E; Ghabdian Y; Rezaei N; Pouya MA; Abdoli A; Malekpour MR; Koohgir K; Saeedi Moghaddam S; Tabarsi P; Moghadami M; Khorvash F; Khodashahi R; Salehi M; Hosseini H
    BMJ; 2023 Sep; 382():e070464. PubMed ID: 37734752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an inactivated vaccine candidate for SARS-CoV-2.
    Gao Q; Bao L; Mao H; Wang L; Xu K; Yang M; Li Y; Zhu L; Wang N; Lv Z; Gao H; Ge X; Kan B; Hu Y; Liu J; Cai F; Jiang D; Yin Y; Qin C; Li J; Gong X; Lou X; Shi W; Wu D; Zhang H; Zhu L; Deng W; Li Y; Lu J; Li C; Wang X; Yin W; Zhang Y; Qin C
    Science; 2020 Jul; 369(6499):77-81. PubMed ID: 32376603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults.
    Mohraz M; Salehi M; Tabarsi P; Abbasi-Kangevari M; Ghamari SH; Ghasemi E; Amini Pouya M; Rezaei N; Ahmadi N; Heidari K; Malekpour MR; Nasiri M; Amirzargar AA; Saeedi Moghaddam S; Larijani B; Hosseini H
    BMJ Open; 2022 Apr; 12(4):e056872. PubMed ID: 35396297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical safety evaluation of intradermal SARS-CoV-2 inactivated vaccine (Vero cells) administration in macaques.
    Yang J; Huo X; Jiang Q; Liao Y; Zhang C; Yu L; Wang Q; Niu T; Li C; Pi N; Li Y; Zhao H; Zhang Y; Tan Y; Liao W; Li Y; Fan S; Li Q
    Vaccine; 2023 Apr; 41(17):2837-2845. PubMed ID: 37003910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies.
    Kozlovskaya LI; Piniaeva AN; Ignatyev GM; Gordeychuk IV; Volok VP; Rogova YV; Shishova AA; Kovpak AA; Ivin YY; Antonova LP; Mefyod KM; Prokosheva LS; Sibirkina AS; Tarasova YY; Bayurova EO; Gancharova OS; Illarionova VV; Glukhov GS; Sokolova OS; Shaitan KV; Moysenovich AM; Gulyaev SA; Gulyaeva TV; Moroz AV; Gmyl LV; Ipatova EG; Kirpichnikov MP; Egorov AM; Siniugina AA; Ishmukhametov AA
    Emerg Microbes Infect; 2021 Dec; 10(1):1790-1806. PubMed ID: 34427172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of active systemic anaphylaxis in guinea pigs upon intramuscular injection of inactivated SARS-CoV-2 vaccine (Vero cells).
    Huang Z; Li Y; Yi H; Wu Z; Li C; Du T; Yang J; Wang Y; Jiang Q; Fan S; Liao Y; Zhang Y; Jiang G; Ma K; Li Q
    Immunopharmacol Immunotoxicol; 2022 Oct; 44(5):633-640. PubMed ID: 35506627
    [No Abstract]   [Full Text] [Related]  

  • 12. Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models.
    Wang ZJ; Zhang HJ; Lu J; Xu KW; Peng C; Guo J; Gao XX; Wan X; Wang WH; Shan C; Zhang SC; Wu J; Yang AN; Zhu Y; Xiao A; Zhang L; Fu L; Si HR; Cai Q; Yang XL; You L; Zhou YP; Liu J; Pang DQ; Jin WP; Zhang XY; Meng SL; Sun YX; Desselberger U; Wang JZ; Li XG; Duan K; Li CG; Xu M; Shi ZL; Yuan ZM; Yang XM; Shen S
    Emerg Microbes Infect; 2020 Dec; 9(1):2606-2618. PubMed ID: 33241728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates.
    Zamani P; Mashreghi M; Rezazade Bazaz M; Zargari S; Alizadeh F; Dorrigiv M; Abdoli A; Aminianfar H; Hatamipour M; Zarqi J; Behboodifar S; Samsami Y; Khorshid Sokhangouy S; Sefidbakht Y; Uskoković V; Rezayat SM; Jaafari MR; Mozaffari-Jovin S
    J Control Release; 2023 Aug; 360():316-334. PubMed ID: 37355212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
    Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
    J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models.
    Li D; Luan N; Li J; Zhao H; Zhang Y; Long R; Jiang G; Fan S; Xu X; Cao H; Wang Y; Liao Y; Wang L; Liu L; Liu C; Li Q
    Emerg Microbes Infect; 2021 Dec; 10(1):2194-2198. PubMed ID: 34736354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animals.
    Offersgaard A; Duarte Hernandez CR; Zhou Y; Duan Z; Gammeltoft KA; Hartmann KT; Fahnøe U; Marichal-Gallardo P; Alzua GP; Underwood AP; Sølund C; Weis N; Bonde JH; Christensen JP; Pedersen GK; Jensen HE; Holmbeck K; Bukh J; Gottwein JM
    Sci Rep; 2024 Jul; 14(1):17039. PubMed ID: 39048693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine.
    Qin E; Shi H; Tang L; Wang C; Chang G; Ding Z; Zhao K; Wang J; Chen Z; Yu M; Si B; Liu J; Wu D; Cheng X; Yang B; Peng W; Meng Q; Liu B; Han W; Yin X; Duan H; Zhan D; Tian L; Li S; Wu J; Tan G; Li Y; Li Y; Liu Y; Liu H; Lv F; Zhang Y; Kong X; Fan B; Jiang T; Xu S; Wang X; Li C; Wu X; Deng Y; Zhao M; Zhu Q
    Vaccine; 2006 Feb; 24(7):1028-34. PubMed ID: 16388880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis.
    Wu X; Xu K; Zhan P; Liu H; Zhang F; Song Y; Lv T
    BMC Infect Dis; 2024 Feb; 24(1):234. PubMed ID: 38383356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates.
    Yao YF; Wang ZJ; Jiang RD; Hu X; Zhang HJ; Zhou YW; Gao G; Chen Y; Peng Y; Liu MQ; Zhang YN; Min J; Lu J; Gao XX; Guo J; Peng C; Shen XR; Li Q; Zhao K; Yang L; Wan X; Zhang B; Wang WH; Wu J; Zhou P; Yang XL; Shen S; Shan C; Yuan ZM; Shi ZL
    Virol Sin; 2021 Oct; 36(5):879-889. PubMed ID: 33835391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.